Formyl Peptide Receptor Signaling in HL-60 Cells through Sphingosine Kinase*

Regina Alemany, Dagmar Meyer zu Heringdorf, Chris J. van Koppen, and Karl H. JakobsDagger

From the Institut für Pharmakologie, Universitätsklinikum Essen, D-45122 Essen, Germany

    ABSTRACT
Top
Abstract
Introduction
References

Sphingosine-1-phosphate (SPP) produced from sphingosine by sphingosine kinase has recently been reported to act as intracellular second messenger for a number of plasma membrane receptors. In the present study, we investigated whether the sphingosine kinase/SPP pathway is involved in cellular signaling of the Gi protein-coupled formyl peptide receptor in myeloid differentiated human leukemia (HL-60) cells. Receptor activation resulted in rapid and transient production of SPP by sphingosine kinase, which was abolished after pertussis toxin treatment. Direct activation of heterotrimeric G proteins by AlF4- also rapidly increased SPP formation in intact HL-60 cells. In cytosolic preparations of HL-60 cells, sphingosine kinase activity was stimulated by the stable GTP analog, guanosine 5'-O-(3-thiotriphosphate). Inhibition of sphingosine kinase by DL-threo-dihydrosphingosine and N,N-dimethylsphingosine did not affect phospholipase C stimulation and superoxide production but markedly inhibited receptor-stimulated Ca2+ mobilization and enzyme release. We conclude that the formyl peptide receptor stimulates through Gi-type G proteins SPP production by sphingosine kinase, that the enzyme is also stimulated by direct G protein activation, and that the sphingosine kinase/SPP pathway apparently plays an important role in chemoattractant signaling in myeloid differentiated HL-60 cells.

    INTRODUCTION
Top
Abstract
Introduction
References

During the last few years, it has become clear that sphingolipids, in addition to being structural constituents of cell membranes, are sources of important signaling molecules. Particularly, the sphingolipid metabolites, ceramide and sphingosine-1-phosphate (SPP),1 have emerged as a new class of potent bioactive molecules, implicated in a variety of cellular processes such as cell differentiation, apoptosis, and proliferation (1-4). Interest in SPP focused recently on two distinct cellular actions of this lipid, namely its function as extracellular ligand activating specific G protein-coupled membrane receptors and its role as intracellular second messenger (5). Important clues to a specific intracellular action of SPP were the following findings. First, activation of various plasma membrane receptors, such as the platelet-derived growth factor receptor (6, 7), the Fcepsilon RI (8), and the Fcgamma RI antigen receptors (9), was found to rapidly increase intracellular SPP production through stimulation of sphingosine kinase. Second, inhibition of sphingosine kinase stimulation strongly reduced or even prevented cellular events triggered by these tyrosine kinase-linked receptors, such as receptor-stimulated DNA synthesis, Ca2+ mobilization, and vesicular trafficking (6, 8, 9). Finally, intracellular SPP was found to mimic the receptor responses, i.e. it stimulated DNA synthesis and mobilized Ca2+ from internal stores (10-14). We recently reported that the G protein-coupled muscarinic acetylcholine receptor subtypes m2 and m3 expressed in HEK-293 cells also induce a rapid and transient SPP production by sphingosine kinase. Furthermore, intracellular injection of SPP rapidly mobilized Ca2+ in intact HEK-293 cells and inhibition of sphingosine kinase markedly inhibited Ca2+ signaling by these and other G protein-coupled receptors (14).

To characterize the mechanisms leading to sphingosine kinase activation by G protein-coupled receptors and the cellular role of this pathway, we investigated whether the formyl peptide receptor stimulates sphingosine kinase in myeloid differentiated human leukemia (HL-60) cells, whether G proteins participate in this process, and, finally, whether sphingosine kinase activation is involved in specific cellular responses to receptor stimulation in HL-60 cells. It is well established that most, if not all, cellular responses to formyl peptide receptors in HL-60 cells and neutrophils, including phospholipase C (PLC) stimulation, Ca2+ mobilization, superoxide production, and enzyme release, are mediated by pertussis toxin (PTX)-sensitive Gi-type G proteins (15). Here, we report that formyl peptide receptor activation rapidly stimulates sphingosine kinase in differentiated HL-60 cells and that G proteins are involved in this process. Moreover, it is shown that inhibition of sphingosine kinase by DL-threo-dihydrosphingosine (DHS) or N,N-dimethylsphingosine (DMS) does not affect PLC stimulation and superoxide production but largely inhibits receptor-stimulated Ca2+ mobilization and enzyme release.

    EXPERIMENTAL PROCEDURES

Materials-- N-Formyl-methionyl-leucyl-phenylalanine (fMLP), lucigenin, dibutyryl cAMP, cytochalasin B, staurosporine, p-nitrophenyl-beta -D-glucuronide, and p-nitrophenyl-beta -D-glucosaminide were obtained from Sigma. GTPgamma S and GDPbeta S were from Boehringer Mannheim. Myo-[2-3H]inositol (24.4 Ci/mmol) was from NEN Life Science Products, D-erythro-[3H]sphingosine (15 Ci/mmol) was from ARC, RPMI 1640 medium was from Life Technologies, Inc., bisindolylmaleimide I (GF 109203X) was from Calbiochem, and PTX was from List Biological Laboratories. All other materials were from previously described sources (14). Immediately before use, stock solutions of the lipids made in methanol or isopropanol were dried down and dissolved in Hanks' balanced salt solution (118 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5 mM D-glucose, and 15 mM HEPES, pH 7.4), containing in addition 1 mg/ml fatty acid-free bovine serum albumin.

HL-60 Cell Culture-- HL-60 cells were grown in RPMI 1640 medium supplemented with 10% fetal calf serum, 150 units/ml penicillin, and 150 µg/ml streptomycin in 5% CO2. Differentiation into neutrophil-like cells was induced by culturing HL-60 cells for 48 h in the presence of 0.5 mM dibutyryl cAMP. For PTX treatment, cells were incubated for 20 h with 50 ng/ml PTX (16, 17).

Assay of Sphingosine Kinase in Intact HL-60 Cells-- Sphingosine kinase-catalyzed formation of SPP was measured as described before (14). In brief, differentiated HL-60 cells (1.8 × 106 cells) equilibrated in Hanks' balanced salt solution/bovine serum albumin for 5 min at 37 °C were incubated with [3H]sphingosine (~105 cpm; final concentration, 30 nM) for 30 s to 10 min at 37 °C in a total volume of 200 µl. The reactions were stopped by addition of 2 ml of ice-cold methanol, followed by 1 ml of chloroform. After vigorous vortexing and incubation for 1 h at 37 °C, particulate matter was pelleted by centrifugation, and the supernatant was evaporated to dryness in a SpeedVac centrifuge. After redissolving in 20 µl of methanol, the samples were spotted onto Silica gel 60 TLC plates (Merck), together with authentic unlabeled sphingosine and SPP. Separation of the products was achieved by TLC in 1-butanol:acetic acid:water (3:1:1) as a solvent system. Sphingosine and SPP spots were visualized by staining with ninhydrin spray. After scraping, radioactivity in the spots was measured by liquid scintillation counting. Formation of [3H]SPP is expressed as cpm/1.8 × 106 cells and corrected for time 0 count rates, amounting to 80-100 cpm.

Assay of Sphingosine Kinase Activity in HL-60 Cytosol-- Differentiated HL-60 cells were suspended in ice-cold lysis buffer (1.2 × 106 cells/ml) containing 100 mM potassium phosphate buffer (pH 7.4), 1 mM EDTA, 10 mM MgCl2, and 1 mM 2-mercaptoethanol and disrupted on ice by 50-100 strokes in a pre-cooled Dounce homogenizer. After centrifugation for 20 min at 50,000 × g and 4 °C, the supernatant (cytosolic fraction) was collected and used directly in sphingosine kinase assays. Enzyme activity was determined for 20 min at 37 °C in a total volume of 200 µl, containing 10 µM [3H]sphingosine (~105 cpm), 1 mM ATP, 10 mM MgCl2, 1 mM EDTA, 1 mM 2-mercaptoethanol, 1 mg/ml fatty acid-free bovine serum albumin, 100 mM potassium phosphate buffer (pH 7.4), and HL-60 cytosol (120-200 µg of protein). Reactions were terminated by addition of 2 ml of ice-cold methanol. Extraction, TLC separation, and quantification of [3H]SPP were carried out as described above. Sphingosine kinase activity is expressed as pmol SPP formed per mg protein and 20 min.

[Ca2+]i Measurements-- Intracellular free Ca2+ concentration ([Ca2+]i) was determined with the fluorescent Ca2+ indicator dye Fura-2 in a Hitachi spectrofluorimeter as described before (18). In some experiments, Ca2+ was omitted from the medium, and in addition 5 mM EGTA was added 2 min before stimulus exposure.

Assay of PLC-- Measurement of PLC-catalyzed inositol phosphate formation was performed as described in detail previously (19). In brief, after labeling for 48 h with myo-[3H]inositol (2.5 µCi/ml) in inositol-free medium, differentiated HL-60 cells were equilibrated for 10 min at 37 °C in Hanks' balanced salt solution/bovine serum albumin with or without the indicated agents. Cells were then incubated with 10 µM fMLP at 37 °C in the presence of 10 mM LiCl for 20 s and 10 min to measure formation of [3H]inositol 1,4,5-trisphosphate (IP3) and total [3H]inositol phosphates, respectively, as reported before (19).

Measurement of Superoxide Anion Generation-- Generation of superoxide anions in differentiated HL-60 cells was measured with the lucigenin assay (20) as described previously (18).

Measurement of Enzyme Release-- Release of beta -glucuronidase and N-acetyl-beta -glucosaminidase enzymes from HL-60 cells was assessed as described (21). Briefly, differentiated HL-60 cells (3.5-5 × 106 cells) were suspended in 500 µl of Hanks' balanced salt solution and incubated for 5 min at 37 °C in the presence of cytochalasin B (5 µg/ml). Reactions initiated by the addition of fMLP were conducted for 5 min at 37 °C and terminated by placement of the tubes on ice. After cell pelleting, activities of beta -glucuronidase and N-acetyl-beta -glucosaminidase enzymes in supernatant fluids and cell lysates were determined as described (22). Release of the enzymes is given as a percentage of the total cellular content.

Data Presentation and Analysis-- Unless otherwise stated, results are presented as the means ± S.E. of three independent experiments, each done in duplicates or triplicates. Statistical analysis was performed by Student's two-tailed t test for unpaired data.

    RESULTS

Formyl Peptide Receptor and G Protein Stimulation of Sphingosine Kinase in HL-60 Cells-- First, we investigated whether the formyl peptide receptor activates the sphingosine kinase in dibutyryl cAMP-differentiated HL-60 cells. For this, formation of [3H]SPP from [3H]sphingosine was determined for various periods of time at 37 °C in the absence and presence of the receptor agonist fMLP, which was applied simultaneously with the radiolabel. Cellular uptake of [3H]sphingosine was fast, reaching 76% of total added after 30 s and 84% after 5 min of incubation, and was not influenced by fMLP (data not shown). Basal conversion of [3H]sphingosine by sphingosine kinase to [3H]SPP was also rapid, and within 2-5 min a plateau of [3H]SPP was reached (Fig. 1A). Activation of the formyl peptide receptor by 10 µM fMLP induced a rapid and transient increase in [3H]SPP production (Fig. 1B). After 2 min, the increase in [3H]SPP reached a maximum of 63 ± 11% (n = 6) above basal [3H]SPP formation in unstimulated cells. Comparable increases in [3H]SPP production were observed in cells stimulated for 2 min with 0.1 µM and 1 µM fMLP. When the measurements were performed in the presence of the sphingosine kinase inhibitors, DHS (30 µM) or DMS (15 µM) (6, 8, 23-25), basal and fMLP-stimulated formation of [3H]SPP were inhibited by 80-90% (data not shown). Together, these results indicate that the formyl peptide receptor is capable of stimulating SPP production by sphingosine kinase in differentiated HL-60 cells.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 1.   Formyl peptide receptor-stimulated SPP formation in HL-60 cells. Formation of [3H]SPP from [3H]sphingosine was determined without (A) and with 10 µM fMLP (B) for the indicated periods of time in differentiated HL-60 cells (3-6 experiments) as described under "Experimental Procedures." In B, values are expressed as percentages of [3H]SPP production relative to unstimulated cells. *, significantly different from unstimulated cells (p < 0.05).

To investigate the signaling pathway leading to sphingosine kinase activation, we studied first whether Gi-type G proteins are involved in the formyl peptide receptor action. Thus, formation of [3H]SPP was measured in control and PTX-treated HL-60 cells. Stimulation of control cells for 2 min with 10 µM fMLP increased [3H]SPP levels by 67 ± 17% over unstimulated cells (Fig. 2A). PTX treatment (50 ng/ml, 20 h) had no effect on basal [3H]SPP production but completely blocked fMLP-induced stimulation of sphingosine kinase, indicating that activation of sphingosine kinase by the formyl peptide receptor is mediated by Gi-type G proteins. To directly assess the role of G proteins in sphingosine kinase stimulation, we studied the effects of direct G protein activation on [3H]SPP formation in intact cells and in a cell-free system. Direct activation of heterotrimeric G proteins by AlF4- in intact HL-60 cells led to a rapid and transient production of [3H]SPP, in a manner similar to the receptor agonist fMLP (Fig. 2B). [3H]SPP levels in cells stimulated for 1, 2, and 5 min with AlF4- amounted to 117, 142, and 46%, respectively, above unstimulated control cells.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 2.   G protein stimulation of sphingosine kinase in intact HL-60 cells. Formation of [3H]SPP from [3H]sphingosine was determined for 2 min in control and PTX-pretreated HL-60 cells in the absence (Basal) and presence of 10 µM fMLP (A) or in control HL-60 cells for the indicated periods of time in the absence (Basal) and presence of AlF4- (10 mM NaF plus 10 µM AlCl3) (B). In A, values are expressed as percentages of [3H]SPP production relative to unstimulated control cells. *, significantly different from basal SPP formation (p < 0.05).

Sphingosine kinase activity has been found to be present in the cytosol of various cell types (4), and purification of a cytosolic sphingosine kinase from rat kidney has recently been reported (26). Therefore, to study G protein regulation of sphingosine kinase in a cell-free system, the effects of various guanine nucleotides on sphingosine kinase activity were investigated in cytosol prepared from differentiated HL-60 cells. Addition of the stable GTP analog GTPgamma S stimulated SPP production by sphingosine kinase in HL-60 cell cytosol by about 50% in a concentration-dependent manner, with an EC50 value of less than 1 µM and a maximal effect at 10-100 µM (Fig. 3A). On the other hand, addition of GTP (100 µM) and the stable GDP analog GDPbeta S (500 µM) did not alter basal sphingosine kinase activity (Fig. 3B). However, GDPbeta S (500 µM) almost fully blocked sphingosine kinase stimulation by GTPgamma S (100 µM). Together, these results indicate that G proteins are signal transduction components in the pathway leading to sphingosine kinase activation in myeloid differentiated HL-60 cells.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 3.   G protein stimulation of sphingosine kinase activity in cytosol of HL-60 cells. Sphingosine kinase activity was determined in HL-60 cytosolic fractions in the presence of the indicated concentrations of GTPgamma S (A) or in the absence (Basal) and presence of 100 µM GTPgamma S, 500 µM GDPbeta S, GTPgamma S plus GDPbeta S, or 100 µM GTP as described under "Experimental Procedures" (B). Values are expressed as percentages of basal sphingosine kinase activity, amounting to 45 ± 6 pmol SPP/mg protein and 20 min (n = 14). *, significantly different from basal sphingosine kinase activity (p < 0.05).

Role of Sphingosine Kinase in Formyl Peptide Receptor Signaling in HL-60 Cells-- Previous studies in other cell types suggested that sphingosine kinase activation represents a Ca2+ signaling pathway for some plasma membrane receptors (8, 9, 14). Because fMLP stimulated sphingosine kinase, we investigated the role of this pathway in Ca2+ mobilization in HL-60 cells. Stimulation of HL-60 cells with fMLP (0.1 nM to 0.1 µM) in the presence of 1 mM extracellular Ca2+ markedly increased [Ca2+]i (Fig. 4A). Maximal increase by about 500 nM was observed at 0.1 µM fMLP. In cells pretreated for 1 min with the sphingosine kinase inhibitor DHS (30 µM), [Ca2+]i increases were reduced by 80-90% at all fMLP concentrations examined, even at a supramaximally effective fMLP concentration of 10 µM (data not shown). Half-maximal inhibition of fMLP (0.1 µM)-stimulated [Ca2+]i increase by DHS was observed at 5.9 ± 0.4 µM (Fig. 4B). A similar inhibition was observed with DMS, another sphingosine kinase inhibitor (IC50 = 5.2 ± 0.9 µM). As exemplified in Fig. 4C, treatment of HL-60 cells with DHS (30 µM) also markedly inhibited the fMLP (1 µM)-stimulated [Ca2+]i increase measured in the absence of extracellular Ca2+.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of sphingosine kinase inhibitors on fMLP-stimulated [Ca2+]i increases. In the presence of 1 mM extracellular Ca2+, increases in [Ca2+]i induced by fMLP at the indicated concentrations were determined in HL-60 cells pretreated for 1 min without (Control) and with 30 µM DHS (A), or [Ca2+]i increases induced by 0.1 µM fMLP were determined in cells pretreated for 1 min with DHS or DMS at the indicated concentrations (B). In B, values are given as percentages of control, the 100% value reflecting the [Ca2+]i increase induced by 0.1 µM fMLP in the absence of inhibitors (519 ± 71 nM, n = 6). C, in the absence of extracellular Ca2+, fMLP (1 µM)-induced [Ca2+]i increase was determined in HL-60 cells pretreated for 1 min without (Control) and with 30 µM DHS. Superimposed tracings are shown. Addition of fMLP is indicated by the arrow.

DHS and DMS by themselves did not cause an increase in [Ca2+]i in HL-60 cells. To dismiss the possibility that the sphingosine kinase inhibitors might deplete intracellular Ca2+ stores, we studied the effect of DHS (30 µM) on [Ca2+]i elevations induced by the endoplasmic reticulum Ca2+-ATPase inhibitor, thapsigargin, in the absence of external Ca2+. In contrast to fMLP stimulation, maximal [Ca2+]i increases induced by thapsigargin (1 µM) were not affected by DHS (control cells, 73 ± 4 nM; DHS-treated cells, 87 ± 4 nM). The time to peak [Ca2+]i after thapsigargin addition, however, was significantly (p < 0.05) increased from 60 ± 8 s in control cells to 103 ± 9 s in DHS-treated cells (data not shown). The inhibitory action of DHS and DMS on fMLP-induced [Ca2+]i increase was not caused by inhibition of PLC stimulation. Preincubation of HL-60 cells for 10 min with 30 µM DHS or 15 µM DMS, strongly reducing Ca2+ mobilization, neither altered basal nor inhibited fMLP (10 µM)-stimulated production of either IP3 or total inositol phosphates (Table I). Furthermore, release of 45Ca2+ induced by IP3 (0.3-20 µM) from 45Ca2+-preloaded saponin-permeabilized cells, measured as described before (27), was not affected by pretreatment of HL-60 cells for 10 min with 30 µM DHS. Finally, because DHS and DMS can act as protein kinase C (PKC) inhibitors (28), we examined whether the inhibition of Ca2+ signaling might be due to PKC inhibition. However, in contrast to DHS and DMS, pretreatment of HL-60 cells with the PKC inhibitors staurosporine (100 nM, 3 min), or bisindolylmaleimide I (100 nM, 15 min) had no effect on the fMLP (0.1 µM)-induced [Ca2+]i elevation, amounting to 605 ± 36 nM in control cells and 637 ± 26 and 591 ± 99 nM in staurosporine- and bisindolylmaleimide I-treated cells, respectively (data not shown).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Lack of effect of DHS and DMS on basal and fMLP-stimulated PLC activities in HL-60 cells
Formation of [3H]IP3 and total [3H]inositol phosphates was determined in differentiated HL-60 cells pretreated for 10 min without (None) and with 30 µM DHS or 15 µM DMS in the absence (Basal) and presence of 10 µM fMLP as described under "Experimental Procedures."

Finally, the role of sphingosine kinase in two well characterized functional responses of myeloid differentiated HL-60 cells to formyl peptide receptor activation was examined, namely production of superoxide anions by NADPH oxidase and enzyme exocytosis. Pretreatment of differentiated HL-60 cells for 1 min with 30 µM DHS did not affect the superoxide production induced either by a maximally effective concentration of fMLP (1 µM) or by a half-maximally effective one (10 nM) (Fig. 5). On the other hand, staurosporine (100 nM) strongly inhibited (by 70 ± 0.5%) the fMLP (1 µM)-stimulated production of superoxide anions (data not shown).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 5.   Lack of effect of sphingosine kinase inhibition on fMLP-stimulated superoxide production. Following pretreatment of HL-60 cells for 1 min with vehicle (Control) or 30 µM DHS, superoxide production induced by 1 µM and 10 nM fMLP was determined as described under "Experimental Procedures." Values are given as percentages of maximum superoxide production measured with 1 µM fMLP. There was no significant difference between control and DHS-treated cells.

In contrast to superoxide production, formyl peptide receptor-stimulated enzyme release was strongly affected by the sphingosine kinase inhibitors. As illustrated in Fig. 6A, pretreatment of HL-60 cells for 5 min with 30 µM DHS or 15 µM DMS inhibited, by 45-50%, the fMLP (1 µM)-stimulated release of beta -glucuronidase. A similar inhibition was observed when the effect of DMS on fMLP (1 µM)-stimulated release of N-acetyl-beta -glucosaminidase was examined (Fig. 6B). Pretreatment with DMS inhibited receptor-stimulated release of this enzyme half-maximally and maximally (about 85% inhibition) at 12 and 20 µM DMS, respectively. Basal enzyme release was not affected by the sphingosine kinase inhibitors. In contrast to DHS and DMS, pretreatment of HL-60 cells with staurosporine (100 nM, 3 min) did not affect fMLP-stimulated beta -glucuronidase release (data not shown).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of sphingosine kinase inhibitors on fMLP-stimulated enzyme release. Following pretreatment of HL-60 cells for 5 min with vehicle (Control), 30 µM DHS or 15 µM DMS (A), or DMS at the indicated concentrations (B), release of beta -glucuronidase (A) and N-acetyl-beta -glucosaminidase (B) was determined in the absence (Basal) and presence of 1 µM fMLP as described under "Experimental Procedures." *, significant inhibition of fMLP-stimulated enzyme release (p < 0.001, 4-11 experiments).


    DISCUSSION

In the present study, we demonstrate that sphingosine kinase catalyzing formation of SPP from sphingosine is rapidly activated by formyl peptide receptors in myeloid differentiated HL-60 cells, a process apparently mediated by Gi-type G proteins, and that sphingosine kinase activity is also stimulated by direct G protein activation, both in intact cells and in a cell-free system. Furthermore, by using the two sphingosine kinase inhibitors DHS and DMS, evidence is provided suggesting that the sphingosine kinase pathway plays an important role in functional responses of HL-60 cells triggered by activation of the formyl peptide receptor. The time course and the magnitude of fMLP-stimulated SPP production in HL-60 cells were comparable with those reported for the G protein-coupled muscarinic receptors expressed in HEK-293 cells and for various tyrosine kinase-linked receptors in other cellular systems (6-9, 14). The sphingosine kinase inhibitors DHS and DMS effectively suppressed basal and fMLP-stimulated SPP formation, indicating that sphingosine kinase is in fact responsible for SPP production in HL-60 cells.

The present study demonstrates for the first time that G proteins are involved in sphingosine kinase activation. First, similar to most other cellular responses of formyl peptide receptors in HL-60 cells and neutrophils (15), the fMLP-induced sphingosine kinase stimulation was completely abolished in PTX-treated cells, indicating participation of Gi-type G proteins. Second, direct activation of heterotrimeric G proteins by AlF4- also markedly increased SPP production in intact HL-60 cells, with a time course similar to that observed for the formyl peptide receptor agonist. Third, the stable GTP analog GTPgamma S stimulated sphingosine kinase activity in HL-60 cytosolic fractions with a concentration-response curve in the µM range, and this stimulation was prevented by the stable GDP analog, GDPbeta S. The identity of the GTP-binding protein mediating the stimulatory effect of GTPgamma S, which can activate both heterotrimeric and low molecular weight GTP-binding proteins, on HL-60 cytosolic sphingosine kinase activity is presently under investigation.

In agreement with our previous findings on muscarinic receptors in HEK-293 cells (14), we provide evidence that the sphingosine kinase pathway is involved in the formyl peptide receptor-mediated Ca2+ mobilization in HL-60 cells. Short-term pretreatment of the cells with the sphingosine kinase inhibitors DHS and DMS potently reduced the fMLP-induced increases in [Ca2+]i, with IC50 values (5-6 µM) in the ranges of those described for inhibition of sphingosine kinase activity (6, 8, 23-25). Control experiments excluded that suppression of Ca2+ signaling by DHS and DMS was caused by PKC inhibition, depletion of internal Ca2+ stores, and perturbation of the PLC/IP3 pathway. It is highly unlikely that the intracellularly formed SPP is released from the cells and stimulates the cells in an autocrine manner, i.e. by activation of plasma membrane sphingolipid receptors. First, there was no evidence of fMLP-stimulated release of [3H]SPP into the medium. Second, similar to results reported before in promyelocytic HL-60 cells (18), extracellularly added SPP only marginally increased [Ca2+]i in differentiated HL-60 cells (by <= 30 nM at 1 µM SPP). Finally, desensitization of this small SPP-induced [Ca2+]i increase by 70% following overnight treatment of the cells with 1 µM SPP did not affect the formyl peptide receptor-induced [Ca2+]i increase (data not shown). The lag time between peak [3H]SPP formation and [Ca2+]i increase most likely results from the time span required for extracellularly applied [3H]sphingosine to cross the plasma membrane and reach intracellular sphingosine kinase to be converted to [3H]SPP. Because SPP and IP3 are generated in a similar time-frame, there may be a concerted action of SPP and IP3 in releasing Ca2+ from internal stores. In this sense, we found that DHS caused a delay in Ca2+ release induced by thapsigargin, without reducing the maximal [Ca2+]i increase by this agent. In lacrimal acinar cells, the thapsigargin-induced [Ca2+]i rise due to leakage of Ca2+ from IP3-sensitive stores has been shown to be dependent on basal levels of IP3 (29). Thus, the absence of SPP after DHS treatment may explain the delay in Ca2+ release induced by thapsigargin. Our data thus suggest that although the formyl peptide receptor strongly stimulates PLC-catalyzed IP3 formation, an intact sphingosine kinase/SPP pathway is required for the receptor-elicited Ca2+ mobilization, similar to the results reported before for other receptors in other cell types (8, 9, 14). Recently, Ca2+ mobilization in Chinese hamster ovary cells by the G protein-coupled receptors for endothelin-1 and thrombin, both strongly stimulating the PLC/IP3 pathway, has been reported to be independent of the IP3 receptor (30). Thus, an alternative or additional mechanism, which may be the sphingosine kinase/SPP pathway, appears to be involved in Ca2+ signaling by these receptors, similar to the results shown here for the formyl peptide receptor in HL-60 cells. At present, the connection between the two pathways in Ca2+ signaling is not clear.

To investigate the physiological role of the sphingosine kinase in chemoattractant signaling, we studied the effects of the sphingosine kinase inhibitors on superoxide production and enzyme release. Production of superoxide anions by the NADPH oxidase in phagocytic cells involves several membrane and cytosolic proteins and can be turned on by various distinct mechanisms, including increase in [Ca2+]i and PKC activation but also by Ca2+- and PKC-independent pathways (31-33). Treatment of HL-60 cells with the sphingosine kinase inhibitor, DHS (30 µM), causing marked inhibition of fMLP-induced [Ca2+]i increase, had no effect on superoxide production induced by fMLP, both at maximally and half-maximally effective concentrations of this stimulus, whereas the PKC inhibitor staurosporine strongly inhibited the fMLP response. These results indicate that sphingosine kinase is apparently not involved in the signaling pathway to NADPH oxidase. In contrast to superoxide production, there is a tight correlation between rises in [Ca2+]i and enzyme exocytosis in HL-60 granulocytes (34). Pretreatment of differentiated HL-60 cells with DHS and DMS strongly inhibited the fMLP-stimulated release of beta -glucuronidase and N-acetyl-beta -glucosaminidase. Moreover, the inhibition of fMLP-induced N-acetyl-beta -glucosaminidase release and [Ca2+]i increase by DMS exhibited a similar concentration dependence, strongly suggesting that inhibition of enzyme release is, at least to a major extent, due to blockade of Ca2+ mobilization. Because the fMLP-stimulated enzyme release was not completely inhibited by DHS or DMS at concentrations effectively blocking fMLP-induced [Ca2+]i rises, it appears that the activated receptor generates additional signals required for exocytosis, e.g. stimulation of phosphatidylinositol 3-kinase (34). Finally, the differential sensitivity of the cellular events triggered by the formyl peptide receptor to DHS and DMS (i.e. no effect on PLC stimulation and superoxide production, but marked inhibition of Ca2+ mobilization and enzyme release) underlines the specificity of the sphingosine kinase inhibitors.

In conclusion, this study demonstrates for the first time that formyl peptide receptors stimulate through PTX-sensitive Gi-type G proteins SPP production by sphingosine kinase in myeloid differentiated HL-60 cells and that this enzyme is also stimulated by direct G protein activation. Furthermore, evidence is provided that the sphingosine kinase/SPP pathway is involved in Ca2+ and exocytosis signaling pathways but apparently not in superoxide production in phagocytic cells.

    FOOTNOTES

* This work was supported by Grant 0310493A from Bayer AG and the Bundesministerium für Bildung und Wissenschaft, Forschung, und Technologie and by a fellowship of the Ministerio de Educacion y Ciencia, Madrid, Spain (to R. A.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Inst. für Pharmakologie, Universitätsklinikum Essen, Hufelandstrasse 55, D-45122 Essen, Germany. Tel.: 49-201-723-3460; Fax: 49-201-723-5968; E-mail: karl.jakobs{at}uni-essen.de.

The abbreviations used are: SPP, sphingosine-1-phosphate; DHS, DL-threo-dihydrosphingosine; DMS, N,N-dimethylsphingosine; fMLP, N-formyl-methionyl-leucyl-phenylalanine; GTPgamma S, guanosine 5'-O-(3-thiotriphosphate); GDPbeta S, guanosine 5'-O-(2-thiodiphosphate); IP3, inositol 1,4,5-trisphosphate; PKC, protein kinase C; PLC, phospholipase C; PTX, pertussis toxin.
    REFERENCES
Top
Abstract
Introduction
References

  1. Hannun, Y. A. (1994) J. Biol. Chem. 269, 3125-3128[Free Full Text]
  2. Heller, R. A., and Krönke, M. (1994) J. Cell Biol. 126, 5-9[Medline] [Order article via Infotrieve]
  3. Kolesnik, R., and Golde, D. W. (1994) Cell 77, 325-328[Medline] [Order article via Infotrieve]
  4. Spiegel, S., and Milstien, S. (1995) J. Membr. Biol. 146, 225-237[Medline] [Order article via Infotrieve]
  5. Meyer zu Heringdorf, D., van Koppen, C. J., and Jakobs, K. H. (1997) FEBS Lett. 410, 34-38[CrossRef][Medline] [Order article via Infotrieve]
  6. Olivera, A., and Spiegel, S. (1993) Nature 365, 557-560[CrossRef][Medline] [Order article via Infotrieve]
  7. Bornfeldt, K. E., Graves, L. M., Raines, E. W., Igarashi, Y., Wayman, G., Yamamura, S., Yatomi, Y., Sidhu, J. S., Krebs, E. G., Hakomori, S., and Ross, R. (1995) J. Cell Biol. 130, 193-206[Abstract]
  8. Choi, O. H., Kim, J.-H., and Kinet, J.-P. (1996) Nature 380, 634-636[CrossRef][Medline] [Order article via Infotrieve]
  9. Melendez, A., Floto, R. A., Gillooly, D. J., Harnett, M. M., and Allen, J. M. (1998) J. Biol. Chem. 273, 9393-9402[Abstract/Free Full Text]
  10. Qiao, L., Kozikowski, A. P., Olivera, A., and Spiegel, S. (1998) Bioorg. Med. Chem. Lett. 8, 711-714[CrossRef][Medline] [Order article via Infotrieve]
  11. Ghosh, T. K., Bian, J., and Gill, D. L. (1990) Science 248, 1653-1656[Medline] [Order article via Infotrieve]
  12. Ghosh, T. K., Bian, J., and Gill, D. L. (1994) J. Biol. Chem. 269, 22628-22635[Abstract/Free Full Text]
  13. Mattie, M., Brooker, G., and Spiegel, S. (1994) J. Biol. Chem. 269, 3181-3188[Abstract/Free Full Text]
  14. Meyer zu Heringdorf, D., Lass, H., Alemany, R., Laser, K. T., Neumann, E., Zhang, C., Schmidt, M., Rauen, U., Jakobs, K. H., and van Koppen, C. J. (1998) EMBO J. 17, 2830-2837[Abstract/Free Full Text]
  15. Ye, R. D., and Boulay, F. (1997) Adv. Pharmacol. 39, 221-289[Medline] [Order article via Infotrieve]
  16. Gierschik, P., Sidiropoulos, D., and Jakobs, K. H. (1989) J. Biol. Chem. 264, 21470-21473[Abstract/Free Full Text]
  17. Wieland, T., Liedel, K., Kaldenberg-Stasch, S., Meyer zu Heringdorf, D., Schmidt, M., and Jakobs, K. H. (1995) Naunyn-Schmiedeberg's Arch. Pharmacol. 351, 329-336[Medline] [Order article via Infotrieve]
  18. van Koppen, C. J., Meyer zu Heringdorf, D., Zhang, C., Laser, K. T., and Jakobs, K. H. (1996) Mol. Pharmacol. 49, 956-961[Abstract]
  19. Schmidt, M., Bienek, C., van Koppen, C. J., Michel, M. C., and Jakobs, K. H. (1995) Naunyn-Schmiedeberg's Arch. Pharmacol. 352, 469-476[Medline] [Order article via Infotrieve]
  20. Bhakdi, S., and Martin, E. (1991) Infect. Immun. 59, 2955-2962[Medline] [Order article via Infotrieve]
  21. Wenzel-Seifert, K., and Seifert, R. (1990) Immunobiology 181, 298-316[Medline] [Order article via Infotrieve]
  22. Absolom, D. R. (1986) Methods Enzymol. 132, 95-180[Medline] [Order article via Infotrieve]
  23. Buehrer, B. M., and Bell, R. M. (1992) J. Biol. Chem. 267, 3154-3159[Abstract/Free Full Text]
  24. Olivera, A., Zhang, H., Carlson, R. O., Mattie, M. E., Schmidt, R. R., and Spiegel, S. (1994) J. Biol. Chem. 269, 17924-17930[Abstract/Free Full Text]
  25. Yatomi, J., Ruan, F., Megidish, T., Toyokuni, T., Hakomori, S., and Igarashi, Y. (1996) Biochemistry 35, 626-633[CrossRef][Medline] [Order article via Infotrieve]
  26. Olivera, A., Kohama, T., Tu, Z., Milstien, S., and Spiegel, S. (1998) J. Biol. Chem. 273, 12576-12583[Abstract/Free Full Text]
  27. Meyer zu Heringdorf, D., Niederdräing, N., Neumann, E., Fröde, R., Lass, H., van Koppen, C. J., and Jakobs, K. H. (1998) Eur. J. Pharmacol. 354, 113-122[CrossRef][Medline] [Order article via Infotrieve]
  28. Igarashi, Y., Hakomori, S., Toyo Kuni, T., Dean, B., Fujita, S., Sugimoto, M., Ogawa, T., El-Ghendy, K., and Racker, E. (1989) Biochemistry 28, 6796-6800[Medline] [Order article via Infotrieve]
  29. Smith, P. M., and Gallacher, D. (1994) Biochem. J. 299, 37-40[Medline] [Order article via Infotrieve]
  30. Mathias, R. S., Mikoshiba, K., Michikawa, T., Miyawaki, A., and Ives, H. E. (1998) Am. J. Physiol. 274, C1456-C1465[Abstract/Free Full Text]
  31. Morel, F., Doussiere, J., and Vignais, P. V. (1991) Eur. J. Biochem. 201, 523-546[Abstract]
  32. Segal, A. W., and Abo, A. (1993) Trends Biochem. Sci. 18, 164-168
  33. Ridley, A. J. (1997) Curr. Biol. 5, 710-712
  34. Nübe, O., Serrander, L., Foyouzi-Yousefi, R., Monod, A., Lew, D. P., and Krause, K.-H. (1997) J. Biol. Chem. 272, 28360-28367[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.